Patents by Inventor Julien Pothier

Julien Pothier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • N-SUBSTITUTED INDOLE DERIVATIVES
    Publication number: 20230165859
    Abstract: The present invention relates to derivatives of formula (I) wherein R1, and R2 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptor EP2.
    Type: Application
    Filed: November 27, 2022
    Publication date: June 1, 2023
    Inventors: Heinz FRETZ, Isabelle LYOTHIER, Julien POTHIER, Sylvia RICHARD-BILDSTEIN, Thierry SIFFERLEN
  • INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE
    Publication number: 20220259212
    Abstract: The present invention relates to compounds of Formula (I) inhibiting indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO) enzymes. Further, their synthesis and their use as medicaments in the treatment of inter alia cancer is disclosed.
    Type: Application
    Filed: July 10, 2020
    Publication date: August 18, 2022
    Inventors: Christoph BOSS, Sylvaine CREN, Thierry KIMMERLIN, Carina LOTZ-JENNE, Julien POTHIER, Naomi TIDTEN-LUKSCH
  • N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS
    Publication number: 20220175775
    Abstract: The present invention relates to derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Application
    Filed: December 13, 2021
    Publication date: June 9, 2022
    Applicant: Idorsia Pharmaceuticals Ltd
    Inventors: Heinz FRETZ, Isabelle LYOTHIER, Julien POTHIER, Sylvia RICHARD-BILDSTEIN, Thierry SIFFERLEN, Lorenza WYDER PETERS, Davide POZZI, Olivier CORMINBOEUF
  • Piperidine CXCR7 receptor modulators
    Patent number: 11306078
    Abstract: The present invention relates to piperidine derivatives of formula (I) wherein Ar1, Ar2, RAr1, R1, R2, and R3 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: April 19, 2022
    Assignee: IDORSIA PHARMACEUTICALS LTD.
    Inventors: Hamed Aissaoui, Philippe Guerry, Francois Lehembre, Julien Pothier, Laetitia Pouzol, Sylvia Richard-Bildstein, Shuguang Yuan
  • Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
    Patent number: 11267824
    Abstract: The present invention relates to compounds of Formula (I) inhibiting indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO) enzymes. Further, their synthesis and their use as medicaments in inter alia cancer is disclosed.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: March 8, 2022
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Daniel Bur, Sylvaine Cren, Thierry Kimmerlin, Carina Lotz-Jenne, Julien Pothier, Naomi Tidten-Luksch
  • N-substituted indole derivatives as PGE2 receptor modulators
    Patent number: 11241431
    Abstract: The present invention relates to derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: February 8, 2022
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Heinz Fretz, Isabelle Lyothier, Julien Pothier, Sylvia Richard-Bildstein, Thierry Sifferlen, Lorenza Wyder Peters, Davide Pozzi, Olivier Corminboeuf
  • INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE
    Publication number: 20200405696
    Abstract: The present invention relates to compounds of Formula (I) inhibiting indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO) enzymes. Further, their synthesis and their use as medicaments in inter alia the treatment of cancer is disclosed.
    Type: Application
    Filed: January 14, 2019
    Publication date: December 31, 2020
    Inventors: Christoph BOSS, Sylvaine CREN, Thierry KIMMERLIN, Carina LOTZ-JENNE, Julien POTHIER, Naomi TIDTEN-LUKSCH
  • PIPERIDINE CXCR7 RECEPTOR MODULATORS
    Publication number: 20200385373
    Abstract: The present invention relates to piperidine derivatives of formula (I) wherein Ar1, Ar2, RAr1, R1, R2, and R3 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.
    Type: Application
    Filed: July 14, 2020
    Publication date: December 10, 2020
    Inventors: Hamed AISSAOUI, Philippe GUERRY, Francois LEHEMBRE, Julien POTHIER, Laetitia POUZOL, Sylvia RICHARD-BILDSTEIN, Shuguang YUAN
  • N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS
    Publication number: 20200289507
    Abstract: The present invention relates to derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Application
    Filed: November 17, 2016
    Publication date: September 17, 2020
    Applicant: Idorsia Pharmaceuticals Ltd
    Inventors: Heinz FRETZ, Isabelle LYOTHIER, Julien POTHIER, Sylvia RICHARD-BILDSTEIN, Thierry SIFFERLEN, Lorenza WYDER PETERS, Davide POZZI, Olivier CORMINBOEUF
  • Piperdine CXCR7 receptor modulators
    Patent number: 10752620
    Abstract: The present invention relates to piperidine derivatives of formula (I) wherein Ar1, Ar2, RAr1, R1, R2 and R3 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: August 25, 2020
    Assignee: IDORSIA PHARMACEUTICALS LTD.
    Inventors: Hamed Aissaoui, Philippe Guerry, Francois Lehembre, Julien Pothier, Laetitia Pouzol, Sylvia Richard-Bildstein, Shuguang Yuan
  • INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE
    Publication number: 20200216467
    Abstract: The present invention relates to compounds of Formula (I) inhibiting indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO) enzymes. Further, their synthesis and their use as medicaments in inter alia cancer is disclosed.
    Type: Application
    Filed: August 16, 2018
    Publication date: July 9, 2020
    Inventors: Christoph BOSS, Daniel BUR, Sylvaine CREN, Thierry KIMMERLIN, Carina LOTZ-JENNE, Julien POTHIER, Naomi TIDTEN-LUKSCH
  • N-SUBSTITUTED INDOLE DERIVATIVES
    Publication number: 20200069686
    Abstract: The present invention relates to derivatives of formula (I) wherein R1, and R2 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptor EP2.
    Type: Application
    Filed: May 17, 2018
    Publication date: March 5, 2020
    Inventors: Heinz FRETZ, Isabelle LYOTHIER, Julien POTHIER, Sylvia RICHARD-BILDSTEIN, Thierry SIFFERLEN
  • PIPERDINE CXCR7 RECEPTOR MODULATORS
    Publication number: 20190169180
    Abstract: The present invention relates to piperidine derivatives of formula (I) wherein Ar1, Ar2, RAr1, R1, R2 and R3 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.
    Type: Application
    Filed: July 27, 2017
    Publication date: June 6, 2019
    Inventors: Hamed AISSAOUI, Philippe GUERRY, Francois LEHEMBRE, Julien POTHIER, Laetitia POUZOL, Sylvia RICHARD-BILDSTEIN, Shuguang YUAN
  • CXCR7 receptor modulators
    Patent number: 10202368
    Abstract: The present invention relates to derivatives of formula (I) wherein (R1)n, ring (A), Y1, Y2, X, R4, L1, L2, and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: February 12, 2019
    Assignee: IDORSIA PHARMACEUTICALS LTD.
    Inventors: Philippe Guerry, Francois Lehembre, Julien Pothier, Hervé Siendt
  • CXCR7 receptor modulators
    Patent number: 9920010
    Abstract: The present invention relates to derivatives of formula (I) wherein (R1)n, R2a, R2b, R3a, R3b, R4, L1, L2, X, Y and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: March 20, 2018
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Heinz Fretz, Philippe Guerry, Thierry Kimmerlin, Francois Lehembre, Julien Pothier, Hervé Siendt, Anja Valdenaire
  • CXCR7 RECEPTOR MODULATORS
    Publication number: 20170327493
    Abstract: The present invention relates to derivatives of formula (I) wherein (R1)n, ring (A), Y1, Y2, X, R4, L1, L2, and A1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.
    Type: Application
    Filed: November 30, 2015
    Publication date: November 16, 2017
    Inventors: Philippe GUERRY, Francois LEHEMBRE, Julien POTHIER, Hervé SIENDT
  • CXCR7 RECEPTOR MODULATORS
    Publication number: 20160107997
    Abstract: The present invention relates to derivatives of formula (I) wherein (R1)n, R2a, R2b, R3a, R3b, R4, L1, L2, X, Y and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.
    Type: Application
    Filed: May 28, 2014
    Publication date: April 21, 2016
    Inventors: Heinz FRETZ, Philippe GUERRY, Thierry KIMMERLIN, Francois LEHEMBRE, Julien POTHIER, Hervé SIENDT, Anja VALDENAIRE
  • 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin Dreceptor modulators
    Patent number: 8575158
    Abstract: The present invention relates to 1-phenyl-substituted heterocyclyl derivatives of the formula (I), wherein X, Y, Z, n, R1, R2, R3, R4, R5, R6, R7 and R10 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
    Type: Grant
    Filed: July 4, 2011
    Date of Patent: November 5, 2013
    Assignee: Actelion Pharmaceuticals Ltd.
    Inventors: Hamed Aissaoui, Christoph Boss, Heinz Fretz, Julien Pothier, Sylvia Richard-Bildstein, Philippe Risch, Romain Siegrist
  • 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS
    Publication number: 20130109685
    Abstract: The present invention relates to 1-phenyl-substituted heterocyclyl derivatives of the formula (I), wherein X, Y, Z, n, R1, R2, R3, R4, R5, R6, R7 and R10 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
    Type: Application
    Filed: July 4, 2011
    Publication date: May 2, 2013
    Applicant: Actelion Pharmaceuticals Ltd.
    Inventors: Hamed Aissaoui, Christoph Boss, Anja Valdenaire, Julien Pothier, Sylvia Richard-Bildstein, Philippe Risch, Romain Siegrist
  • Aminopyrazole derivatives
    Patent number: 8288419
    Abstract: The invention relates to aminopyrazole derivatives of formula (I), wherein A, E, R1 and R2 are as defined in the description, their preparation and their use as pharmaceutically active compounds.
    Type: Grant
    Filed: December 12, 2008
    Date of Patent: October 16, 2012
    Assignee: Actelion Pharmaceuticals, Ltd
    Inventors: Daniel Bur, Oliver Corminboeuf, Sylvaine Cren, Heinz Fretz, Corinna Grisostomi, Xavier Leroy, Julien Pothier, Sylvia Richard-Bildstein